Table 1

Baseline characteristics

Total patient population
(n=221)
EULAR good responders
(n=87)
EULAR non-responders and moderate responders
(n=134)
Demographics
 Age, mean (SD), years54 (12)53 (12)55 (12)
 Sex, female, n (%)176 (80)63 (72)113 (84)*
Disease status
 Disease duration, median (IQR)8 (3–18)7 (3–17)10 (4–18)
 Rheumatoid factor positive, n (%)160 (72)59 (68)101 (75)
 Anti-CCP-positive, n (%)155 (70)60 (69)95 (71)
 Erosive disease, n (%)163 (74)63 (72)100 (75)
 ESR, median (IQR), mm/h24 (12–41)18 (9–29)30 (15–49)***
 C-reactive protein, median (IQR), mg/L12 (6–24)12 (5–22)11 (6–29)
 DAS28, mean (SD)5.3 (1.1)5.0 (0.9)5.4 (1.2)**
(co) medication
 Prior DMARDs, mean (SD)3.2 (1.4)3.0 (1.4)3.3 (1.4)
 Prior biologicals, n (%)54 (24)9 (10)45 (34)***
 Methotrexate use, n (%)170 (77)77 (89)93 (69)**
 Methotrexate dose, median (IQR), mg/week15 (5–25)25 (12.5–25)14 (0–25)**
 Prednisone use, n (%)71 (32)31 (36)40 (30)
 Prednisone dose, median (IQR), mg/day7.5 (5–10)5 (5–7.5)7.5 (5–10)
  • *p<0.05; **p<0.01; ***p<0.001.

  • CCP, cyclic citrullinated peptide; DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism.